24/05/2010 20:30:00

TRADE NEWS: Agilent Technologies and Stemina Biomarker Discovery Announce Efforts to Accelerate Stem Cell Metabolite Biomarker D

Related content


Technologies Inc. (NYSE:A) and Stemina

Biomarker Discovery, Inc. today announced efforts to accelerate

Stemina’s metobolomic research. Stemina uses metabolomic analysis of

stem cells for the discovery of biomarkers for use in drug screening and

drug development.

Agilent is providing a 1290

Infinity UHPLC system to separate stem cellular metabolites, coupled

to a 6530

Accurate Mass quadrupole time-of-flight mass spectrometer (Q-TOF MS)

to identify those metabolites. Agilent also is providing Mass

Profiler Professional software to help Stemina researchers interpret

the complex data generated by metabolomics experiments.

“We are pleased to broaden our relationship with Agilent to advance our

scientific platform and our discovery of important small molecules

involved in developmental toxicity and autism,” said Beth Donley,

Stemina CEO. “We have used Agilent technology since Stemina began

operations in 2007 and have been very pleased with the instrumentation,

support and collaboration we have experienced with Agilent.”

“Metabolomics is a major growth area for us, and the innovative work

being done at Stemina is the kind we like to support,” said Gustavo

Salem, Agilent vice president and general manager, Biological Systems

Division. “We’ve aggressively built an LC/MS portfolio for the life

sciences in recent years, and the Mass Profiler Professional software

provides the crucial ability to visualize biological pathways from the

massive and complex data sets generated by metabolomics studies.”

About Stemina Biomarker Discovery, Inc.

The Stemina research team, founded on research by Chief Scientific

Officer Gabriela Cezar, D.V.M., Ph.D., Chief Scientific Officer, is

focused on the discovery, development and commercialization of molecular

biomarkers to improve drug safety and human health. Paul R. West, Ph.D.,

is the company’s Director of BioAnalytical Chemistry. Stemina’s cell

based assays arise from the strategic convergence of two cutting edge

technologies: human embryonic stem (hES) cells and metabolomics. Stemina

uses Agilent mass spectrometry systems to analyze the small molecules

secreted by hES cells, and differentiated cells such as heart and neural

cells made from hES cells, in response to drugs, injury or disease. The

company’s research has made significant progress in metabolomic

profiling of human embryonic stem cell response to dosing with

pharmaceutical agents. The result of this work is “devTox™”, an assay to

screen pharmaceutical agents for teratogenicity. Information about

Stemina is available at www.stemina.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is the world’s premier measurement

company and a technology leader in communications, electronics, life

sciences and chemical analysis. The company’s 16,000 employees serve

customers in more than 110 countries. Agilent had net revenues of $4.5

billion in fiscal 2009. Information about Agilent is available on the

Web at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive

news is available on the Agilent news site at www.agilent.com/go/news.


Stuart Matlow, +1 408-553-7191





Donley, +1 608-577-9209


Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

G4S plc UK : Holding(s) in Company

28/04/2017 15:48:39
For filings with the FCA include the annex   For filings with issuer exclude the annex     TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi     ..

Dimensional Fund Advisors Ltd. : Form 8.3 - John Wood Group Plc - Ordinary shares

28/04/2017 13:55:58
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Form 8.5 (EPT/RI) - Tesco plc

28/04/2017 09:31:35
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Tecnotree’s Annual Report and the Corporate Governance and Remuneration Statements 2016
ABN AMRO announces completion of the sale of its private banking activities in Asia and the Middle East
European Energy A/S: Agreement signed for the sale of a wind farm in Denmark with a gross capacity of 25.05 MW
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in The Toronto-Dominion Bank of Class Action Lawsuit and Upcoming Deadline – TD
Total number of shares and voting rights in Zealand at April 30, 2017

Related stock quotes

Agilent Technologies Inc 55.05 -0.7% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
01 May 2017 01:25:54
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseCandidateBuild_20170427.1 - EUROWEB6 - 2017-05-01 02:25:54 - 2017-05-01 01:25:54 - 1000 - Website: OKAY